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nary disease (COPD) overlap syndrome (ACOS) have more rapid
disease progression and more exacerbations than do those with either
condition alone. Little research has been performed, however, in these
patients. Objective: The objective was to summarize the health care
utilization, costs, and comorbidities of patients with uncontrolled
asthma and patients with ACOS. Methods: This retrospective analy-
sis used medical and pharmacy claims from large commercial health
plans. The study included patients 6 years or older with a diagnosis of
asthma and one or more asthma exacerbation (index event). Patients
were classiﬁed as having asthma alone or ACOS, and the two groups
were matched for age, sex, region, index year, index month, and
health plan type. Outcomes included rates of comorbid disease,
health care utilization, and costs during the 12 months before and
after the index exacerbation. Results: Among the matched patients
with asthma (6,505 ACOS; 26,060 without COPD), mean annualee front matter Copyright & 2015, International S
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01.all-cause health care costs were twice as high as for patients with
ACOS ($22,393 vs. $11,716; P o 0.0001). Asthma-related costs, repre-
senting 29% of total costs, were nearly twice as high among patients
with ACOS ($6,319 vs. 3,356; P o 0.0001). Cost differences were driven
by large differences in the proportions of patients with an inpatient
hospitalization (34.0% vs. 14.6%; Po 0.0001) or emergency department
visit (29.6% vs. 19.9%; P o 0.0001). Nearly all prespeciﬁed comorbid
conditions were more prevalent in the ACOS group. Conclusions:
Patients with asthma and COPD had nearly double the health care
costs as did patients with asthma without COPD. The overall disease
proﬁle of patients with asthma should be considered when managing
patients, rather than treating asthma as a solitary condition.
Keywords: asthma, claims data, COPD, overlap syndrome.
Copyright & 2015, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
An estimated 25.5 million Americans have been diagnosed with
asthma [1], and nearly 18 million adults have been diagnosed
with chronic obstructive pulmonary disease (COPD) [2]. These
diseases impose a substantial burden on both the health care
system and the society. The latest estimate in 2007 cited a total
cost of $57.28 billion annually for asthma, including $43.57 billion
in direct costs for medications and health care services and $13.7
billion in indirect costs associated with lost productivity because
of missed days of school or work [3]. In 2007, asthma was the
source of 13.9 million outpatient visits, 1.75 million emergency
department (ED) visits, and 456,000 hospitalizations [4]. COPD
carries a similarly large economic burden, with a projected
economic impact of $49.9 billion due to the direct and indirect
costs of COPD in 2010 [5], and it has been estimated that patientswith COPD incur an excess of $6000 in annual health care costs
per patient than do those without COPD [6]. In addition, there
were more than 15 million outpatient visits and 739,000 hospital-
izations due to COPD in 2009, and in 2008 COPD accounted for
56.7% of all deaths due to lung disease [7].
Despite advances in asthma management, up to 50% of the
patients with asthma have uncontrolled disease, where control has
been deﬁned as having no marker for moderate to severe exacer-
bations (an ED visit for asthma, a hospital admission for asthma, or
a ﬁlled prescription of an oral corticosteroid [OCS] over a 12-month
period) and no more than 3 or 10 doses of short-acting β2-agonists
(SABA) per week depending on the severity of asthma [8]. Of patients
with uncontrolled asthma, 70% had at least one unscheduled ofﬁce
visit, 36% had at least one ED visit, and 14% had at least one
hospitalization in 2005 [9]. Patients with uncontrolled asthma had
more absences from work or school, used greater health careociety for Pharmacoeconomics and Outcomes Research (ISPOR).
rsson are employees of AstraZeneca. David M. Kern, Siting Zhou,
d subsidiary of WellPoint, Inc.
ustry Sponsored Research, 800 Delaware Avenue, Fifth Floor,
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 7 5 9 – 7 6 6760resources, and had more than double the health care costs than did
patients with controlled asthma [10,11]. Reasons for the lack of
control have generally focused on the undertreatment of asthma,
while the impact of comorbidities has not been thoroughly explored.
Although asthma and COPD are distinct conditions, their
symptoms are similar and the differential diagnosis may there-
fore be difﬁcult [12,13]. Furthermore, asthma and COPD often
occur together, referred to as asthma-COPD overlap syndrome
(ACOS), and with other comorbid conditions [12–15]. Prevalence
of the asthma-COPD overlap has been reported at rates higher
than 50% in other observation studies [16–18], while clinical
studies have also identiﬁed this overlap pattern. In a recent
Italian study, the prevalence of comorbid asthma and COPD
was 1.6% among people aged between 20 and 44 years, 2.1% in
those 45 to 64 years old, and 4.5% in those aged 65 years or older,
accounting for 16%, 30%, and 61% of all asthma cases in each age
group, respectively [12]. Soriano et al. [19] found that 17% of a US
population and 19% of a UK population surveyed demonstrated
more than one obstructive airway disease, and the prevalence of
asthma-COPD overlap increased with age for both men and
women. Compared with those who have only asthma or COPD,
individuals who have both conditions have more rapid disease
progression, more exacerbations, increased hospitalizations, a
greater number of comorbidities, and a lower health-related
quality of life [12,13,15,20]. All these are expected to lead to an
increase in costs.
The present study used recent medical and pharmacy insur-
ance claims data from a large US health plan to analyze differ-
ences in health care utilization and resulting costs of patients
with ACOS versus patients with asthma without COPD, among
those with uncontrolled disease, deﬁned as having at least one
asthma exacerbation during a 4-year intake period. The results of
this study aim to ﬁll an evidence gap for ACOS by providing real-
world data regarding demographic characteristics, comorbidities,
health care costs, and resource use of uncontrolled patients with
asthma exacerbations, and to serve as a foundation for future
clinical trials and observational studies.Methods
Study Design and Setting
This retrospective cohort analysis used administrative claims
data obtained from the HealthCore Integrated Research Environ-
ment (HIRE). HIRE contains a broad, clinically rich, and geo-
graphically diverse spectrum of longitudinal claims data for
approximately 35.9 million members of commercial health plans
in the United States. The database represents claims from the
largest commercially insured population in the United States and
includes lines of business such as health maintenance organiza-
tions, point-of-service, preferred provider organizations, and
indemnity plans.
Researchers had access to only a limited data set. Strict
measures were taken to preserve patient anonymity and con-
ﬁdentiality as well as to ensure full compliance with the 1996
Health Insurance Portability and Accountability Act.
Patient Selection
The study includes patients aged 6 years and older who had a
diagnosis of asthma between January 1, 2007, and December 31,
2010. All patients had at least one asthma exacerbation during the
4-year intake period, which was deﬁned as a prescription ﬁll for
an OCS, or an ED visit with an asthma diagnosis (deﬁned using the
International Classiﬁcation of Diseases, 9th Revision, Clinical Modiﬁca-
tion codes 493.0x, 493.1x, and 493.9x), or an inpatient visit with aprimary diagnosis of asthma [21]. The date of the ﬁrst exacer-
bation during the intake period was considered the index date.
For inclusion in the study, patients were also required to have
at least one asthma diagnosis and at least one pharmacy claim
for an asthma medication within the 12 months before the index
date and at least 12 months continuous health plan enrollment
before and after the index event. There were no exclusion criteria
for this study.
ACOS Cohort
Patients with asthma were split into two mutually exclusive
cohorts on the basis of their COPD status in the preindex period.
Patients with at least one medical claim including a diagnosis of
COPD (International Classiﬁcation of Diseases, 9th Revision, Clinical
Modiﬁcation code 491.xx [chronic bronchitis], 492.xx [emphysema],
494.xx [bronchiectasis], or 496.xx [chronic airway obstruction
NOS]) during the 12-month preindex period were categorized as
patients with ACOS; patients with no diagnosis of COPD were
categorized as patients with asthma without COPD.
Outcome Measures
The primary outcome was the utilization (inpatient, ED visits,
and outpatient visits, and asthma-related prescription ﬁlls) and
resulting health care costs (total costs paid by the patient and the
health plan) in the 12 months before and after the exacerbation.
Asthma-related health care resource utilization and costs were
deﬁned as any medical claim with at least one diagnosis of
asthma or a pharmacy claim for respiratory-related medication.
Prescriptions are not linked to medical diagnoses in the database,
and thus medications were considered respiratory-related med-
ications on the basis of their medication class and indication, not
a diagnosis. Respiratory medication use was identiﬁed by at least
one pharmacy claim for controller medication, including inhaled
corticosteroids (ICS), long-acting β2-agonists, combination ICS/
long-acting β2-agonist agents, leukotriene receptor antagonists,
theophylline, and omalizumab, or rescue medication, including
SABA and OCS. All-cause health care costs include the costs of all
resource utilization (outpatient and ofﬁce visits, inpatient hospi-
talizations, ED visits, skilled nursing facility stays, and prescrip-
tion ﬁlls) for any reason or diagnosis. All-cause pharmacy costs
include the costs of all medications, for the treatment of any
disease or condition, ﬁlled in a pharmacy. For both asthma-
related and all-cause events, the costs for laboratory testing and
all procedures are included within the setting they were per-
formed (physician’s ofﬁce, other outpatient setting, ED, inpatient
hospitalization, etc.).
Statistical Analysis
To examine differences in comorbid conditions, health care
utilization, and costs between patients with ACOS and patients
with asthma without COPD, a technique similar to that of
propensity score matching was used to create comparable ACOS
and non-COPD cohorts. Because part of the objective of this study
was to observe differences in patient comorbidities, the goal of
the matching was not to balance on all potential covariates as is
commonly the case when using propensity scores to match two
treatment groups, but rather to achieve balance on a few very
general characteristics between two disease groups. Because of
these differences, we refrain from calling this propensity score
matching. Because the number of patients without COPD greatly
outnumbered those with the condition, patients were matched
1:4 (ACOS: asthma without COPD). A logistic regression model
was used to model the probability of a patient having COPD
(similar to a propensity score) predicted by age (continuous), sex,
geographic region, index year, index month, health plan type,
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type. The predicted probabilities of having COPD were then
sorted in descending order. A Greedy matching algorithm was
used to match each patient with COPD, starting with the case
with the highest predicted probability of having COPD, to four
patients without COPD who had predicted probabilities closest to
that of the case. Controls could be matched to only one case;
thus, after a case was matched with its four controls, the next
case could be matched only to the pool of controls that did not
include those who were matched with a previous case. The two
groups were required a priori to be balanced on age, sex, region,
index year, index month, and health plan type (P 4 0.05 for each
characteristic). It was also prespeciﬁed that the matching algo-
rithm should retain at least 50% of the eligible patients with
ACOS to preserve generalizability to the ACOS population. Clin-
ical characteristics and comorbidities were not used as matching
criteria because it was the focus of the study to understand how
patients with asthma with and without COPD were inherently
different in terms of comorbidities, resource utilization, and
costs. Comparisons of baseline characteristics before and after
matching were performed using t tests for differences in mean
age and chi-square tests for testing differences in categorical
distributions.
After matching, logistic regression was used to compare
differences in proportions of dichotomous variables (comorbid
conditions, medication use, and resource utilization), negative
binomial models were used to compare the mean number of
visits, and gamma regression with a log link was used for
analyzing cost data in the 12-month window after the index date.
Analysis was unadjusted for any potential confounders, and a
P value of less than 0.05 was considered statistically signiﬁcant.
All analyses were performed using SAS v9.2 (Cary, NC).
Sensitivity Analysis
A sensitivity analysis was performed for all cost outcomes among
the subgroup of individuals whose index exacerbation event was
either an asthma-related inpatient hospitalization or an ED visit
(i.e., those that were identiﬁed only by an OCS ﬁll were excluded).
This was done to increase conﬁdence that the population truly
had uncontrolled asthma and were not included solely because of
an OCS ﬁll for non–asthma-related symptoms.Results
Unmatched ACOS and Non-COPD Asthma Populations
Baseline Characteristics
A total of 94,883 patients with asthma met the study inclusion
criteria (see Appendix A in Supplemental Materials found at
http://dx.doi.org/10.1016/j.jval.2015.04.010). Most of the patients
were female, with a mean age of 41.6 years (Table 1). Patients
were distributed relatively evenly across the four geographic
regions of the United States. Before matching, patients with
ACOS were more than 20 years older on average than patients
with asthma without COPD (61.7 and 38.4 years, respectively).Asthma exacerbations and Medication Use
The most common type of index asthma exacerbation was an
OCS prescription ﬁll (84%) followed by an asthma ED visit (15%)
and asthma inpatient hospitalization (0.9%). During the 12-
month postindex period, 47.8% of the patients had an additional
asthma exacerbation, a rate that was nearly 20 percentage points
higher in patients with ACOS than in patients with asthma
without COPD (59.3% and 40.8%, respectively).A comparison of asthma medication use in the preindex and
postindex periods illustrates that most of the patients with
asthma used rescue medications and controller medications
were underutilized. During the preindex period, 25.8% did not
have any asthma controller, and the corresponding ﬁgure was
30.2% for the postindex period. During the 12 months before the
index exacerbation, only one of four patients (25.1%) had at least
one ICS monotherapy prescription ﬁll (Fig. 1), which was similar
between patients with ACOS and those without COPD. Use of ICS/
long-acting β2-agonists combination therapy was more common
among patients with ACOS (51.5%) than among those without COPD
(37.7%), and rescue SABA use was slightly more common among
patients without COPD (75.9%) than among those with ACOS
(68.7%). The difference in controller use between groups was similar
during the 12 months after the index exacerbation, whereas little
difference was seen in rescue medication use between those with
and without COPD in the 12 months postindex.
Comorbid Conditions
Overall, patients with ACOS had more comorbidities. Of the most
common comorbidities reported during the preindex period in the
unmatched population, patients with ACOS had higher rates of
hypertension (63.2% vs. 25.3% of those without COPD) and dyslipi-
demia (53.0% vs. 26.0%), but lower rates of allergic rhinitis (27.1%
vs. 38.7%) and sinusitis (28.0% vs. 30.2%) (Fig. 2). In addition,
differences between cohorts with and without COPDwere observed
for certain other comorbidities including gastroesophageal reﬂux
disease (27.0% of ACOS vs. 13.1% without COPD), diabetes mellitus
(24.0% vs. 8.1%), and cardiovascular diseases (11.6% vs. 1.9%).
Matched Populations
A total of 6,515 patients from the ACOS cohort and 26,060 patients
without COPD were matched. After matching, all the included
prespeciﬁed variables (age, sex, region, index year, index month,
and health plan type) were well balanced with P values of 0.05 or
more. Adjusted results for the prevalence of comorbid conditions
within matched patients with asthma with and without COPD are
shown in Figure 2. Although closer in magnitude after matching,
indicating that unmatched differences were partly due to age, sex,
and other differences, patients with ACOS after matching continued
to have higher rates of most comorbid conditions before the index
time, including dyslipidemia (46.2% vs. 40.8% among those without
COPD; odds ratio [OR] ¼ 1.25; 95% conﬁdence interval [CI] 1.18–1.32),
hypertension (50.1% vs. 38.7%; OR ¼ 1.59; 95% CI 1.51–1.68), gastro-
esophageal reﬂux disease (25.9% vs. 17.6%; OR ¼ 1.64; 95% CI 1.54–
1.75), and diabetes mellitus (20.1% vs. 12.6%; OR ¼ 1.76; 95% CI 1.64–
1.88). Patients without COPD continued to have higher rates of
allergic rhinitis (31.1% vs. 37.4%; OR ¼ 0.76; 95% CI 0.71–0.80), while
the matched population no longer was different in terms of sinus-
itis between groups (32.6% vs. 31.8%; OR ¼ 1.03; 95% CI 0.98–1.10).
After matching, the presence of any of the prespeciﬁed cardiovas-
cular disease diagnoses (stroke/transient ischemic attack/cerebro-
vascular disease, coronary artery disease, peripheral vascular
disease, chronic heart failure, myocardial infarction, unstable
angina) was found in 25.2% of the patients with ACOS and 11.0%
of the patients in the asthma-only group.
Resource Use
After matching, there remained large differences in rates of
inpatient hospitalization observed between the two groups dur-
ing the preindex period (34.0% of the patients with ACOS having
Z1 inpatient visit vs. 14.6% of those without COPD; OR ¼ 3.01;
95% CI 2.83–3.21; P o 0.0001), as well as differences in ED visits
(29.6% vs. 19.9% with Z1 visit; OR ¼ 1.69; 95% CI 1.59–1.79;
P o 0.0001) (Table 2). Results were similar when considering only
asthma-related events, though with slightly smaller effect sizes,
Table 1 – Characteristics of patients with asthma before and after matching.
Characteristic Before matching After matching
Asthma without
COPD (N ¼ 81,946)
Patients with ACOS
(N ¼ 12,937)
P value* Asthma without
COPD (N ¼ 26,060)
Patients with ACOS
(N ¼ 6,515)
P value*
Age (y), mean  SD 38.4  20.1 61.7  16.0 o0.0001 50.7  13.4 50.8  13.4 0.6493
Sex: female 50,729 (61.9) 8,452 (65.3) o0.0001 18,053 (69.3) 4,470 (68.6) 0.2995
Index year o0.0001 0.1611
2007 33,802 (41.2) 7,157 (55.3) 12,793 (49.1) 3,097 (47.5)
2008 19,344 (23.6) 2,548 (19.7) 5,732 (22.0) 1,466 (22.5)
2009 15,988 (19.5) 1,840 (14.2) 4,252 (16.3) 1,101 (16.9)
2010 12,812 (15.6) 1,392 (10.8) 3,283 (12.6) 851 (13.1)
Index month o0.0001 0.9095
January 9,755 (11.9) 2,478 (19.2) 3,819 (14.7) 930 (14.3)
February 8,771 (10.7) 1,559 (12.1) 2,927 (11.2) 739 (11.3)
March 8,607 (10.5) 1,497 (11.6) 2,966 (11.4) 708 (10.9)
April 7,461 (9.1) 1,216 (9.4) 2,436 (9.3) 624 (9.6)
May 7,102 (8.7) 1,062 (8.2) 2,160 (8.3) 572 (8.8)
June 5,731 (7.0) 803 (6.2) 1,833 (7.0) 431 (6.6)
July 5,031 (6.1) 735 (5.7) 1,548 (5.9) 398 (6.1)
August 5,046 (6.2) 644 (5.0) 1,581 (6.1) 402 (6.2)
September 5,916 (7.2) 694 (5.4) 1,593 (6.1) 406 (6.2)
October 6,586 (8.0) 787 (6.1) 1,829 (7.0) 461 (7.1)
November 6,165 (7.5) 753 (5.8) 1,714 (6.6) 427 (6.6)
December 5,775 (7.0) 709 (5.5) 1,654 (6.3) 417 (6.4)
Health plan type o0.0001 0.0576
HMO 17,755 (21.7) 3,125 (24.2) 5,410 (20.8) 1,327 (20.4)
PPO 56,857 (69.4) 8,758 (67.7) 18,806 (72.2) 4,668 (71.7)
CDHP 2,564 (3.1) 150 (1.2) 454 (1.7) 139 (2.1)
Other
commercial
4,770 (5.8) 904 (7.0) 1,390 (5.3) 381 (5.8)
Region o0.0001 0.0716
Northeast 19,875 (24.3) 3,038 (23.5) 6,275 (24.1) 1,512 (23.2)
Midwest 22,492 (27.4) 4,123 (31.9) 7,002 (26.9) 1,817 (27.9)
South 21,996 (26.8) 3,267 (25.3) 6,964 (26.7) 1,793 (27.5)
West 17,583 (21.5) 2,509 (19.4) 5,819 (22.3) 1,393 (21.4)
Note. Values are n (%) except indicated otherwise.
ACOS, asthma and COPD overlap syndrome; CDHP, consumer-driven health plan; COPD, chronic obstructive pulmonary disease; HMO, health
maintenance organization; PPO, preferred provider organization.
* P value for difference overall between groups. Age was analyzed via a t test; all other variables were analyzed via chi-square tests.
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CI 2.10–2.44; P o 0.0001) and ED visits (6.3% vs. 4.2%; OR ¼ 1.55;
95% CI 1.38–1.74; P o 0.0001). During the postindex period,
patients with ACOS continued to see higher rates of utilization
than did those without COPD, but to a slightly smaller extent
than what was observed during the preindex period (Table 2).Health Care Costs
The higher resource utilization resulted in a near doubling of all-
cause and asthma-related health care costs for the ACOS cohort
in the year before and the year after the index exacerbation. In
the preindex period, the mean annual all-cause costs were higher
for patients with ACOS ($22,393 vs. $11,716; mean difference ¼
$10,677; 95% CI $10,057–$11,315; P o 0.0001), and a similar trend
was seen in asthma-related costs ($6,319 vs. $3,356; mean differ-
ence ¼ $2,963; 95% CI $2,737–$3,197; P o 0.0001) (Fig. 3). Similar
results were seen in the 12-month postindex period for both
mean all-cause costs ($24,168 vs. $14,059; mean difference ¼
$10,109; 95% CI $9,417–$10,821; P o 0.0001) and asthma-related
costs ($5,579 vs. $3,648; mean difference ¼ $1,931; 95% CI $1,711–
$2,160; P o 0.0001). Only around 30% of the total costs were
related to asthma, illustrating the impact of comorbidities and
treatment of other conditions.For the sensitivity analysis, the subgroup of individuals whose
index exacerbation event was either an asthma-related inpatient
hospitalization or an ED visit included 3593 individuals without
COPD and 764 patients with ACOS. All-cause cost results
remained consistent with the original analysis, with mean
annual all-cause costs higher for patients with ACOS during the
postindex period ($23,827 vs. $14,899; mean difference ¼ $8,928;
95% CI $7,765–$10,007; P o 0.0001). Similarly, for asthma-related
costs, while higher in both groups compared with the original
analysis, there remained a similar magnitude of difference
($8,339 vs. $5,939; mean difference ¼ $2,401; 95% CI $1,874–
$2,885; P o 0.0001).Discussion
Knowledge about the cost of different diseases is useful in
planning and implementation of relevant health-policy interven-
tions. This study analyzed the costs of asthma by comparing
costs for patients with asthma with comorbid COPD to those
without. It is well known that asthma is a disease with high costs,
but to understand the full picture, it is important to consider that
patients with asthma often have comorbidities, which may
increase the economic burden dramatically. A main objective of
Fig. 1 – Use of respiratory-related medications in the preindex and postindex periods for the unmatched population. ACOS,
asthma and COPD overlap syndrome; COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroids; LABA, long-
acting β2-agonists; LTRA, leukotriene receptor antagonists; OCS, oral corticosteroids; SABA, short-acting β2-agonists.
*Includes OCS use identiﬁed as the index exacerbation. (Color version of ﬁgure is available online.)
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and those with ACOS, separately, in terms of comorbidities. This
study does not attempt to identify any causalities or associations
between comorbidities, nor does it assess whether uncontrolled
asthma or COPD acts as a confounder or effect modiﬁer for any
other comorbidity.
Studies have shown that patients with ACOS have greater
health care resource utilization, including more exacerbations,
increased hospitalizations, and more outpatient and physician
ofﬁce visits [12,13,15]. A study of Medicaid participants estimated
that these increases in utilization led to substantially higher healthFig. 2 – Comorbid conditions during the 12-month preindex per
and COPD overlap syndrome; COPD, chronic obstructive pulmon
transient ischemic attack. (Color version of ﬁgure is available oncare costs, including an incremental annual cost of $12,607 for
asthma patients with comorbid COPD ($14,914) compared with
those without COPD ($2,307) [13]. Our study found a similar
magnitude of difference in costs, with patients with ACOS incurring
more than $10,000 more in health care costs; however, costs for
both groups were much higher overall compared with what was
found in the Medicaid study. The results of our study are consistent
with what was found recently by Andersen et al. [22]. Using a large
Finnish cohort, the investigators found that patients with ACOS had
a nearly threefold increase in the number of hospitalizations on
average compared with patients with asthma (6.0 vs. 2.1 from 2000iod for unmatched and matched populations. ACOS, asthma
ary disease; GERD, gastroesophageal reﬂux disease; TIA,
line.)
Table 2 – Health care resource utilization during the preindex and postindex periods for the matched
population.
Health care
utilization type
Patients with asthma
without COPD (COPD–)
Patients with
ACOS (COPDþ)
COPDþ vs. COPD– (reference)
Estimate* 95% CI P value
Lower Upper
Number of patients 26,060 6,515
12-mo preindex period
All-cause health care utilization
Inpatient hospitalization 3,803 (14.6) 2,214 (34.0) 3.01 2.83 3.21 o0.0001
Number of events, mean  SD† 1.4  1.0 1.7  1.4 0.36 0.29 0.43 o0.0001
Length of stay/patient, mean  SD† 4.5  8.5 8.2  15.3 3.63 3.13 4.16 o0.0001
Emergency department visit 5,196 (19.9) 1,927 (29.6) 1.69 1.59 1.79 o0.0001
Ofﬁce visit 25,985 (99.7) 6,498 (99.7) 1.10 0.65 1.87 0.7148
Other outpatient visit 24,594 (94.4) 6,347 (97.4) 2.25 1.92 2.65 o0.0001
Asthma-related health care utilization
Inpatient hospitalization 2,383 (9.1) 1,208 (18.5) 2.26 2.10 2.44 o0.0001
Number of events, mean  SD† 1.2  0.5 1.3  0.7 0.14 0.06 0.22 0.0004
Length of stay/patient, mean  SD† 4.3  7.9 7.3  14.4 3.00 2.46 3.58 o0.0001
Emergency department visit 1,089 (4.2) 412 (6.3) 1.55 1.38 1.74 o0.0001
Ofﬁce visit 22,973 (88.2) 5,277 (81.0) 0.57 0.53 0.62 o0.0001
Other outpatient visit 8,238 (31.6) 2,655 (40.8) 1.49 1.41 1.57 o0.0001
12-mo postindex period
All-cause health care utilization
Inpatient hospitalization 4,013 (15.4) 1,922 29.5% 2.30 2.16 2.45 o0.0001
Number of events, mean  SD† 1.5  1.2 1.9  1.8 0.44 0.36 0.52 o0.0001
Length of stay/patient, mean  SD† 5.7  12.0 9.6  16.8 3.88 3.24 4.56 o0.0001
Emergency department visit 8,214 (31.5) 2,432 (37.3) 1.29 1.22 1.37 o0.0001
Ofﬁce visit 25,848 (99.2) 6,466 (99.2) 1.08 0.79 1.48 0.6191
Other outpatient visit 24,803 (95.2) 6,298 (96.7) 1.47 1.27 1.70 o0.0001
Asthma-related health care utilization
Inpatient hospitalization 2,315 (8.9) 819 (12.6) 1.48 1.36 1.61 o0.0001
Number of events, mean  SD† 1.3  0.8 1.4  0.9 0.14 0.04 0.23 0.0034
Length of stay/patient, mean  SD† 5.0  9.1 8.0  13.8 3.01 2.33 3.77 o0.0001
Emergency department visit 4,656 (17.9) 1,092 (16.8) 0.93 0.86 1.00 0.0364
Ofﬁce visit 17,452 (67.0) 3,886 (59.6) 0.73 0.69 0.77 o0.0001
Other outpatient visit 7,733 (29.7) 2,116 (32.5) 1.14 1.08 1.21 o.0001
Notes. Statistical comparisons are comparing patients with COPD to patients without COPD (reference group); i.e., Mean difference ¼ mean
(COPDþ) – mean (COPD–), and OR ¼ Odds (COPDþ)/Odds (COPD–). Values are n (%) unless otherwise indicated.
ACOS, asthma and COPD overlap syndrome; CI, conﬁdence interval; COPD, chronic obstructive pulmonary disease; OR, odds ratio.
* Odds ratio from logistic regression is used for dichotomous variables, mean difference from negative binomial models for count variables.
† Including only patients with at least one inpatient hospitalization.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 7 5 9 – 7 6 6764to 2009). This is consistent with the present study which showed
that patients with ACOS had more than 2.5 the cost ($4128 vs.
$1549) due to asthma-related hospitalizations in the preindex
period and 2.0 the cost ($3053 vs. $547) in the postindex period,
when compared with patients with asthma. Our study is the ﬁrst to
compare health care costs of patients with asthma with and
without COPD in a commercially insured US population.
The results of this study using data obtained from medical and
pharmacy claims show that most of the patients were uncontrolled
and possibly undertreated, with a higher proportion of patients
ﬁlling rescue medications than controller therapy. In addition, our
study showed negligible changes in medication use between the
preindex and postindex periods, including a slight decrease in the
proportion of patients with controller use. Practice guidelines
recommend physicians to consider prescribing long-term controller
medications at discharge, such as ICS, for patients who do not
currently use a controller, in addition to continued short-term
treatment with SABA and OCS [23]. Furthermore, before the latest
2014 Global Initiative for Asthma report [24], guidelines did not
consider the comorbid proﬁle of patients, including no speciﬁcguidelines for asthma with COPD, but instead focus on asthma
alone. This study provides evidence that there are important
differences between patients with asthma and COPD and patients
with asthma without COPD that should be considered when
managing the treatment of these patients.
The results demonstrated that patients with asthma and COPD
have a higher rate of additional comorbid conditions than do those
who do not have COPD, even after matching for age, sex, and some
baseline demographic characteristics. Furthermore, after matching
on these factors, health care costs among patients with COPD were
roughly double that of patients with asthma alone. All-cause costs
were substantially higher than asthma-related costs, which high-
lights the importance of recognizing and treating comorbidities in
patients with asthma, especially those with comorbid COPD.
Asthma and COPD are not singular diseases but rather parts of
different pathological mechanisms, and treatment needs to shift
from a focus on a single disease to controlling multiple comorbid-
ities. The goal of this study was not to look at the effect of COPD
alone in addition to asthma, but instead to examine the array of
comorbid conditions that are present in patients with ACOS versus
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increased costs and comorbid COPD alone in an asthma population
would require further analysis.
Both aging and obstructive airway diseases are associated with
complex comorbidities. Symptoms of asthma, COPD, and other
comorbidities may overlap, treatmentsmay interact, the underlying
pathophysiology may be shared, and the natural history of all
conditions may be altered. As a consequence, guidelines for asthma
and other chronic conditions should include consideration of
multiple comorbidities. These multiple comorbidities may inﬂuence
the clinical manifestations and natural history of asthma and
should be taken into account in the diagnosis, assessment of
severity and prognosis, and management of the disease. Better
understanding of the epidemiology of multimorbidity is necessary
to develop interventions to prevent it, reduce its burden, and align
health care services more closely with patients’ needs [25].
Together, asthma and COPD comprise the two most prevalent
chronic lung diseases worldwide [26]. One of the essential chal-
lenges facing clinicians caring for patients with these disorders is
that although both share a spectrum of signs and symptoms and
are characterized physiologically by expiratory airﬂow limitation,
they represent distinct entities with apparently distinct pathogen-
eses. Clinical practice guidelines have attempted to differentiate
between asthma and COPD in clinically meaningful ways, typically
incorporating some combination of epidemiologic and clinical
characteristics to help differentiate the disorders. Signiﬁcant clin-
ical and physiologic overlap between asthma and COPD, however,
makes distinguishing the two diseases and integrating clinical,
physiologic, and inﬂammatory data to optimize outcomes a chal-
lenge [16]. It is important to recognize that this group of patients
has been systematically excluded from many clinical trials, and
therefore evidence about their management is limited despite the
fact that this phenotypic group tends to have more frequent
exacerbations and more health care use [14]. Furthermore, a strong
case has been made for the use of integrated care pathways (ICPs)
by a group of European researchers [27]. The authors deﬁne ICPs as
“structured multidisciplinary care plans which detail essential
steps in the care of patients with a speciﬁc clinical problem… ICPs
differ from practice guidelines as they are utilised by a multi-
disciplinary team, and focus on the quality and co-ordination of
care” [27]. Thus, it is of utmost importance to understand the
totality of disease burden, not just one or two speciﬁc conditions,
for any disease state. We believe that results of the present study
support this approach as it pertains to patients with asthma alone
and those with asthma and COPD. It is clear that patients withACOS differ from patients with asthma in terms of health care
costs, but they also have other comorbid conditions beyond COPD
that need to be considered when managing their health.
Study Limitations
Patients with COPD were identiﬁed on the basis of the presence of
one medical claim with a diagnosis for COPD. This deﬁnition of
COPD, although speciﬁc in terms of International Classiﬁcation of
Diseases, 9th Revision codes used, is fairly broad as it could also
include patients with a single rule-out diagnosis of COPD. If this is
the case, however, the group of patients with asthma and COPD
would contain patients who are truly COPD free and thus differ-
ences observed between the two groups (ACOS vs. asthma without
COPD) could somewhat underestimate the true effect because of
the dilution of the ACOS group; conversely, if the cost due to other
comorbidities in patients with single rule-out COPD is higher than
that in patients with true COPD, costs may be overestimated.
Furthermore, results of pulmonary function tests were not available
in the claims database and would be useful for increased speciﬁcity
in diagnosing both asthma and COPD. In addition to lacking access
to pulmonary function tests, there were no data available on other
clinical measures such as computed tomography scans and cytol-
ogy results, which would be instrumental in phenotyping the
patients with COPD to better understand their disease [28]. Unfortu-
nately, this epidemiologic database study is limited to insurance
claims, and COPD was identiﬁed using International Classiﬁcation of
Diseases, 9th Revision diagnosis codes; therefore, it is unknown how a
physician submitting a claim arrived at the diagnosis of COPD.
The population was restricted to patients with asthma with
uncontrolled disease because patients with uncontrolled disease
drive health care costs because of ED and inpatient hospital-
izations. Thus, the results may not be generalizable to patients
with asthma with controlled disease (i.e., those without an ED or
inpatient hospitalization for asthma or an OCS ﬁll).
Although the pharmacy claims in the present study provided
evidence that prescriptions were ﬁlled, it is unknown whether
patients used their medication as prescribed. Thus, it is possible
that some patients who ﬁlled controllers after their initial event
were, in fact, untreated. Conversely, some patients we considered
untreatedmight have hadmedication on hand from earlier ﬁlls [29].
OCS use accounted for the vast majority of asthma exacerba-
tions, and it cannot be determined whether OCS use was for a
COPD or an asthma exacerbation, although for purposes of this
study it was always considered an asthma exacerbation. In
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 7 5 9 – 7 6 6766addition, because OCS use is not speciﬁc to asthma treatment,
considering an OCS ﬁll as an index event may have resulted in the
inclusion of patients who did not truly have uncontrolled asthma.
To examine the potential bias that may have been introduced by
including patients with nonexacerbating asthma, we conducted a
sensitivity analysis including only those individuals whose index
event was a severe exacerbation, that is, an asthma-related
inpatient hospitalization or ED visit. The results of this analysis
were consistent with the original analysis; there remained a large
increase in costs for patients with ACOS compared with patients
with asthma who did not have comorbid COPD.
The Medicare and Medicaid population is underrepresented in
HIRE data. HIRE captures claims for members who use supple-
mental Medicare insurance but does not include the claims and
services provided and reimbursed by the Centers for Medicaid &
Medicare Services or other entities contracted directly by the
Centers for Medicaid & Medicare Services. Other general limita-
tions of commercial claims are also present. Data cannot be
generalized to the US population, but are broadly representative
of the commercially insured population in the United States.
Health care utilization was based on having a claim for the
condition of interest (i.e., asthma), which can either overestimate
or underestimate actual utilization for any given patient or
population. Administrative claims data are primarily collected
for billing and reimbursement purposes and may be subject to
potential coding biases, inconsistencies, and missing data and
may be affected by the absence of clinical data. Last, other
unobserved characteristics, such as race, education, and smoking
status, may have affected the observations.Conclusions
This real-world analysis of patients with asthma experiencing an
asthma exacerbation demonstrated a high degree of comorbid
COPD among patients with asthma (ACOS). At the index exacer-
bation, patients with ACOS had higher prevalence rates of addi-
tional comorbidities, and in the following year they demonstrated
greater health care utilization and nearly double health care costs,
largely driven by inpatient hospitalizations. The overall disease
proﬁle of patients with asthma needs to be considered when
managing patients rather than treating asthma as a solitary
condition, because control of the overall comorbid burden can
lead to a reduction in serious events, resulting in a reduction in the
cost of inpatient hospitalization and overall health care cost.Acknowledgment
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